Fundraising FoxNextech Invest
Venture capitalActively deployingZurich · Seed–Late Stage · 43 people tracked
Also known as NEXTECH INVEST LTD.
Find your way into Nextech Invest
Sign up to see every warm intro you have to Nextech Invest
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nextech Invest team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Nextech Invest focuses on precision medicine, identifying and funding emerging biotechnology companies developing transformative cancer treatments. Operating from Zurich, Switzerland, the firm invests in companies worldwide and supports its portfolio through pivotal stages of scientific validation and value creation.
Source: firm website, verified Oct 1, 2026.
Team · 43 people
from the firm's website & public directories
Founder mafia
2 people who came through Nextech Invest went on to found or lead other companies.
What they invest in
from 65 of 77 portfolio companiesBiotech ×61Healthtech ×30Medical Devices ×23Deep Tech ×15AI & Machine Learning ×10Digital Health ×9Longevity ×2Data & Infrastructure ×1
HQs:United States×44Canada×2Germany×1United Kingdom×1Croatia×1Japan×1
Who they back
founder profiles across 35 portfolio companiesFounding team size:solo founder×182 founders×83 founders×54+ founders×4
Where their founders studiedfrom 28 founders with education data
University of California, Berkeley ×4Massachusetts Institute of Technology ×3Stanford University ×3University of Pennsylvania ×3Columbia University ×2Harvard University ×2Princeton University ×2Stanford University School of Medicine ×2
What their founders studiedfrom 27 founders with field-of-study data
Life Sciences ×17Chemistry ×11Medicine ×4Business & Management ×3Computer Science ×2
Where their founders worked beforefrom 29 founders with career history
Atlas Venture ×3Amunix Pharmaceuticals ×2GNF ×2Raze Therapeutics, Inc. ×2Third Rock Ventures ×2
22 founders hold a PhD · 2 hold an MBA (of 27 with degree data)
Investments · 77 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 32024 · 72023 · 42022 · 22021 · 92020 · 42019 · 42018 · 22017 · 12016 · 22015 · 143 dated
Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.
BiotechHealthtechMedical DevicesRedwood City, US
Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)
Board seatThilo Schroeder· per SEC Form D
Co-investorsBain Capital Life SciencesForesite CapitalGen CapitalGV (Google Ventures)Illinois VenturesThe Column Group+2 more
Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.
BiotechBoston, US
Alan Huang(Executive Officer)inAdam Crystal(Executive Officer)inDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)
BoardBarbara Weber(Executive Officer, Director)in
Board seatKanishka Pothula· per SEC Form D
Co-investorsForesite CapitalNSG VenturesThird Rock Ventures
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalHBM Healthcare InvestmentsHBM PartnersOrbiMedSamsara BioCapitalSR One Capital Management+3 more
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)inManuel Litchman(Executive Officer, Director)inRandy Teel(President and Chief Executive Officer; Director)inCraig Crews(Founder)
BoardStephen Squinto(Director)inLiam Ratcliffe(Director)in
Co-investors5AM VenturesAccess BiotechnologyCanaan PartnersConnecticut InnovationsRA CapitalSolasta Ventures+2 more
Autolus Therapeutics develops engineered T cell therapies targeting cancer and autoimmune diseases using proprietary cell programming technology; the company commercializes AUCATZYL, an FDA-approved CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia in adults, and maintains a clinical pipeline evaluating additional indications including pediatric leukemia, lupus nephritis, and multiple sclerosis.
London
Martin Pulé(Senior Vice President, Founder, Chief Scientific Officer)Christopher Williams(Senior Vice President, Chief Business Development Officer)Edgar Braendle(Executive Officer)inChristopher Vann(Executive Officer)inDavid Brochu(Executive Officer)inChristian Itin(Chief Executive Officer and Director)in
Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.
Elizabeth Buck(Chief Scientific Officer)inBrent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)
Co-investorsLAVLilly Asia VenturesNew Enterprise Associates (NEA)NSG VenturesRA CapitalVersant Ventures+4 more
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersRA CapitalWellington ManagementAlexandriaCity Hill VenturesSectoral Asset Management+3 more
C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.
BiotechCambridge, US
Kenneth C. Anderson(Director)Andrew J. Hirsch(Director and Chief Executive Officer)in
BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)
Co-investors3E Bioventures CapitalBain Capital Life SciencesRA CapitalCobro Ventures
Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors.
BiotechHealthtechPhiladelphia, US
Martin Lehr(Founder)inJennifer Minai-Azary(Executive Officer)inAlex Levit(Executive Officer)Linda Beth West(Director)Richard Jay Berman(Director)Philip Kantoff(Director)in
Co-investorsOUP (Osage University Partners)Torrey Pines Investment
Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.
BiotechHealthtechMedical Devices
Mary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)Jennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)inNadim Ahmed(President and Chief Executive Officer)in
Co-investorsForesite CapitalBiotechnology Value FundOrbiMed
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Paul Stone(Executive Officer)inYujiro S. Hata(President, Chief Executive Officer and Director)
BoardTimothy Shannon(Director)inJohn Diekman(Director)inTerry Rosen(Director)Jeffrey Stein(Director)
Co-investors5AM VenturesCanaan PartnersGV (Google Ventures)Biotechnology Value FundWuXi Healthcare Ventures
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
PINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inTroy Wilson, Ph.D., J.D.(Co-founder; President, Chief Executive Officer and Chairman of the Board)Kevan M. Shokat, Ph.D.(Founding team member)HEIDI HENSON(Executive Officer)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalOUP (Osage University Partners)
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures Fund+7 more
ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.
BiotechHealthtechSouth San Francisco, US
Richard Heyman(Chairman, Founder, Scientific Advisory Board)inCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Dominic Piscitelli(Chief Financial Officer)inPratik Multani(Chief Medical Officer)inJacob Chacko(President, Chief Executive Officer and Board Member)in
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Taiho Ventures, LLCThe Column GroupViking GlobalOrbiMed
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)+9 more
.png)
Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.
AI & Machine LearningBiotechDeep TechCambridge, US
Donald A. Bergstrom(Executive Officer)inSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)
Co-investorsCommonweal VenturesEcoR1 CapitalForesite CapitalNat TurnerSoftBank Vision FundCurie.Bio+2 more
Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.
BiotechLondon
Craig Tooman(Executive Officer)inGiles Campion(Executive Officer)Mark Rothera(Executive Officer, Director)inBarbara Ruskin(Executive Officer)
BoardJames Ede-Golightly(Director)Alistair Gray(Director)
Co-investorsForesite CapitalMC Healthcare VenturesVivo Capital
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.
BiotechHealthtechCarlsbad, US
Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)inAlan Fuhrman(Executive Officer)inTodd Harris(President, Chief Executive Officer and Director)inBhavesh Ashar(Chief Operating Officer)in
Co-investorsAlta PartnersBioBritCanaan PartnersRA Capital
Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.
BiotechHealthtechVancouver, US
ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)inSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in
Co-investorsBrace PharmaCTI Life Sciences Fund L.P.HBM Healthcare InvestmentsLumira VenturesWUTIF CapitalAmplitude Venture Capital
BiotechBurlingame, US
Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)inTimothy Smith(Executive Officer)
BoardPeter Thompson(Director)inCarol Gallagher(Director)in
Board seatAlfred Scheidegger· per SEC Form D
Co-investorsAstellas Venture Management LLCNew Enterprise Associates (NEA)OUP (Osage University Partners)5AM VenturesClarus VenturesOrbiMed+1 more
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Board seatBenjamin Cravatt· per SEC Form D
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsCardinal PartnersSoftBank Vision FundAlexandriaALTITUDE LIFE SCIENCE VENTURES+4 more
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechDeep TechDigital HealthHealthtechMedical DevicesAgoura Hills, US
C. Alexander Kamb(Director)inJim Robinson(CEO)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardSrini Akkaraju(Director)in
Co-investorsMana VenturesThe Column GroupVida VenturesSamsara BioCapital
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.
BiotechLongevityMedical DevicesBoston, US
Co-investorsFrazier Life SciencesWUTIF CapitalAscenta CapitalBiotechnology Value FundLightspeed Venture PartnersLongitude Capital+1 more
Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)inRyan B. Corcoran(Director, Promoter)Richard Heyman(Founder)
BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in
Co-investorsCanaan PartnersOrbiMedVida VenturesDigitalis VenturesNVIDIA
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesInkefMission BiocapitalMRL Ventures FundRA Capital
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesHBM Healthcare InvestmentsHBM PartnersOUP (Osage University Partners)+2 more
ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.
BiotechHealthtechMedical DevicesSan Diego, US
Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)
BoardJonathan Leff(Director)
Co-investorsOrbiMedRA CapitalSR One Capital ManagementSofinnova Ventures
Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.
BiotechHealthtechMedical Devices
Bryan E. Stuart(Chief Executive Officer)inMarion Dorsch(President and Chief Scientific Officer)inJared Rutter(Founder)John Tallarico(Founder)Ralph DeBerardinis(Founder)
Co-investorsLux CapitalRA CapitalThe Column Group
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)inTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)Zaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)
Co-investorsEcoR1 CapitalFrazier Life SciencesIllumina VenturesSanofi VenturesVida VenturesGoldman Sachs+1 more
Co-investorsAlta PartnersARCH Venture PartnersDC Investment PartnersLongwood FundPathway to CuresAtlas Venture+6 more
Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.
BiotechHealthtechCambridge, US
Nick Lydon(Director)Christoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in
BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)
Co-investorsF-Prime CapitalForesite CapitalRA CapitalRidgeback CapitalWellington ManagementThird Rock Ventures
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsRed Tree VentureSamsara BioCapitalWellington ManagementAlly Bridge GroupJanus Henderson InvestorsPerceptive Xontogeny Venture+1 more
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)
BoardThilo Schroeder(Director)inWalter H. Moos(Director)
Co-investorsBerkeley CatalystHemisphere Ventures LLCJude GomilaLifeforce CapitalMission Bay CapitalMission Biocapital+3 more
Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.
BiotechHealthtechCambridge, US
Kevin Marks(Founder)in
Co-investorsGV (Google Ventures)Taiho Ventures, LLCAlexandria
Diamond Therapeutics is a preclinical biotechnology company developing drug treatments for psychiatric and neurological disorders, with a focus on the pharmacology and therapeutic use of psychedelic compounds.
BiotechHealthtechMental HealthToronto, CA
Judy Blumstock(Chief Executive Officer, Founder, Director)inMichael B. McDonnell(Chief Medical Officer)Grant McCutcheon(Chief Financial Officer)in
Co-investorsJLSNoeticPalo Santo VCNew Enterprise Associates (NEA)RA Capital
EQRx was a Cambridge, MA biopharma that aimed to sell lower-priced novel drugs; it was acquired by Revolution Medicines in 2023.
Alexis Borisy(Founder)
Co-investorsAndreessen HorowitzArboretum VenturesARCH Venture PartnersGV (Google Ventures)Bain CapitalCasdin Capital+1 more
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuinAlan Saghetelian
Co-investorsNewpath PartnersCRV (Charles River Ventures)Raptor GroupSamsara BioCapitalBiotechnology Value FundCasdin Capital+1 more
Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.
AI & Machine LearningFuture of WorkHR TechTokyo, JP
Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))
Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalCasdin CapitalInvus+2 more
Flare is a Shopify app that lets merchants set delivery-date rules by postcode, product, and shipping method so customers only see fulfillable dates at checkout, with automation for cut-off times, order tagging, and 3PL syncing.
E-commerceLogistics & Supply ChainRetail TechSaaSLondon, GB
Daniel Parekh-Hill(CEO)inAlex Hooper(CTO)in
Co-investorsEntrepreneur FirstAgent CapitalBase10 PartnersCasdin CapitalInovia CapitalInvus+3 more
Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.
AI & Machine LearningBiotechDeep TechHealthtech
Jim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)Jacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in
Co-investorsNexTech VenturesPfizer VenturesThird Rock VenturesPfizer Venture InvestmentsShangBay Capital LLCAgent Capital
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Prospect Venture PartnersRho Capital PartnersRho VenturesRiverVest Venture Partners+2 more
Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.
BiotechDeep TechHealthtechMenlo Park, US
Colin James Bell Harvey(Director)Brian T. Naughton(Director)inMaureen Hillenmeyer(CEO & Co-Founder)in
BoardAlex Kolich(Director)
Co-investorsATEL VenturesB3 HoldingSoftBank Vision FundThe Column Group8VCCasdin Capital+1 more
Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.
BiotechHealthtechNew York, US
Sean Algeo(Executive Officer, Promoter)inMark A. McCamish(Executive Officer, Director)inDavid M. Tanen(Executive Officer, Promoter)
BoardDavid Chang(Director, Promoter)Helen Kim(Director)Jakob Loven(Director)in
Co-investorsGV (Google Ventures)Wellington ManagementVida Ventures
IDRx discovers, develops and delivers medicines and vaccines focused on cancer, HIV, respiratory diseases, and infectious diseases.
BiotechMedical Devices
Co-investorsAndreessen HorowitzRA Capital
ITM is a vertically integrated biotechnology company specializing in precision oncology through radioisotope production and radiopharmaceutical development, with clinical programs advanced through subsidiary Lumara Bio.
BiotechHealthtechMedical Devices
Alexander Pironi(Executive Vice President, Global Head of Radioisotopes)inDr. Konstantin Zhernosekov(Chief Scientific Officer & Managing Director ITM Medical Isotopes & ITM Oncologics)
Co-investorsCapmontRV Invest GmbH
Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.
BiotechCambridge, US
Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)inRichard Murray(Executive Officer, Director)
BoardRobert Tepper(Director)inCary Pfeffer(Director)inRobert Kamen(Director)in
Co-investorsBoutique Venture PartnersGENERAL INCEPTIONSofinnova VenturesVenture Capital Investment ManagementThird Rock VenturesWellington Management
A biotechnology company developing cancer therapies for patients with unmet medical needs.
BiotechHealthtech
Co-investorsAtlas VentureF-Prime CapitalEight Roads Ventures
Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.
BiotechMedical Devices
Co-investorsForesite CapitalAlexandriaLilly Asia VenturesLongwood Fund
BiotechSan Diego, US
Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)
BoardBret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)in
Co-investorsForesite CapitalViking GlobalJanus Henderson InvestorsRA CapitalVenrock Healthcare Capital PartnersViking Global Investors
Kronos Bio was a clinical-stage biopharmaceutical company developing small molecule therapeutics that target deregulated transcription factor networks implicated in cancer.
BiotechNew York, US
Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)
BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)
Co-investorsEcoR1 CapitalGV (Google Ventures)Vida VenturesBlackRockCommodore CapitalInvus+2 more
Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.
BiotechHealthtechMedical Devices
Co-investorsAccess BiotechnologyAtlas VentureAccess IndustriesForbionRA Capital
Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).
BiotechHealthtechCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)
Co-investorsBain Capital Life SciencesF-Prime CapitalLightstone VenturesNew Enterprise Associates (NEA)Pfizer Venture InvestmentsRho Ventures+3 more
Mirati develops investigational medicines and treatments for patients with multiple myeloma and other oncology indications.
BiotechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsBioBritBoxer Capital, LLCPappas Capital
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
Biotech
Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in
Co-investorsLifeSci Venture PartnersThird Rock VenturesAlexandriaCasdin CapitalCreacion VenturesGoldman Sachs+3 more
BiotechCambridge, US
Richard Gaynor, M.D.(Executive Officer)inRobert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)inEric Lander(Director)Hugh Dowd(Executive Officer, Director)
BoardCary Pfeffer, M.D.(Director)
Co-investorsSofinnova VenturesClal Biotechnology IndustriesThird Rock VenturesWellington Management
Nextop IO provides a mobile content delivery network with a client-side library for iOS and Android that routes traffic through optimized proxy servers, reducing latency, improving throughput, and lowering data and battery consumption for mobile applications connecting to backend services.
Data & InfrastructureDeveloper ToolsEnterprise Software
Brien Colwell(CEO)in
Co-investorsY CombinatorAndreessen HorowitzLightspeed Venture PartnersRA Capital
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Co-investorsCurative VenturesForesite CapitalRidgeback CapitalThe Column GroupVida Ventures
The Faculty of Pharmacy and Biochemistry offers pharmacy and biochemistry degree programs, including a Pharmacy programme in English aligned with EU Directive 2005/36/EC for EU/EEA registration.
EdTech
Co-investorsVesna AdvisorsRA CapitalThe Column Group
PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function.
BiotechHealthtechCranbury, US
David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Director)
BoardPeter Thompson(Director)inSteve Winick(Director)Arnold Oronsky(Director)
Co-investorsAvoro Capital AdvisorsOUP (Osage University Partners)RA CapitalViking GlobalWellington ManagementOrbiMed
Acquired by Genmab in April 2024.
Co-investorsB Capital GroupB4 CapitalHongShan Capital GroupLAVLifeSci Venture PartnersLilly Asia Ventures+2 more
.jpeg){kind=logo}
Sail Biomedicines develops RNA-based medicines using a platform integrating Endless RNA and targeted nanoparticle delivery technology.
AI & Machine LearningBiotechDeep TechCambridge, US
John Mendlein(Executive Chairman)
Co-investorsFlagship PioneeringQuan Capital
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesVida VenturesAbingworth+3 more
BiotechDigital HealthMedical DevicesSeattle, US
Peter A. Thompson(Executive Officer, Director)in
Co-investorsEcoR1 CapitalPontifax Venture CapitalRA CapitalUS Venture PartnersAlexandriaOrbiMed
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.
BiotechHealthtechCambridge, US
Aaron Ring(Co-founder)inAashish Manglik(Co-founder)inJeff Landau(Chief Executive Officer)inRoland Gendron(Chief Business Officer)inMichelle Zhang(Chief Scientific Officer)in
BoardVineeta Agarwala(Director)in
Co-investorsRA CapitalAndreessen HorowitzGV (Google Ventures)Magnetic VenturesOMX VenturesAxial VC+1 more
A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.
BiotechDeep TechMedical DevicesWilmington, US
Liangxing Wu(Executive Officer, Director)inWenqing Yao(Executive Officer, Director)inTing Feng(Director)Wenqing Yao, Ph.D.(Founder & CEO)Liangxing Wu, Ph.D.(Co-Founder & SVP Drug Discovery)
BoardReid Huber(Director)in
Co-investorsThe Innovation SpaceThird Rock Ventures
BiotechCambridge, US
William C. Shakespeare(Director)in
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)inCarl Gordon(Director)in
Co-investorsForesite CapitalLongitude CapitalNexTech VenturesOmega FundsOrbiMedPontifax Venture Capital+2 more
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersAscenta CapitalBayern KapitalBioMedPartnerscoparionFrazier Life Sciences+7 more
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.
AI & Machine LearningBiotechDeep TechHealthtechStanford, US
Thorsten Stafforst(Chairman of the Board of Directors)inKris ElveruminTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in
BoardRodger Novak(Chair)in
Co-investors+ND CapitalARCH Venture PartnersForbionVenrockFast Track InitiativeLifelink+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ambrx BiopharmaAset TherapeuticsAutolusLaronde BioRelay TherapeuticsTurning Point TherapeuticsTurning Point Therapeutics (Alumni)
Exits · 28
19 IPOs · 9 acquisitions · showing 23Revolution MedicinesNASDAQ: RVMDTango TherapeuticsNASDAQ: TNGXAlumisNASDAQ: ALMSArvinas Holding Co. LLCNASDAQ: ARVNAutolus Therapeutics plcNASDAQ: AUTLBlack Diamond Therapeutics, IncNASDAQ: BDTXBoundless BioNASDAQ: BOLDC4 TherapeuticsNASDAQ: CCCCContext TherapeuticsNASDAQ: CNTXCullinan TherapeuticsNASDAQ: CGEMIdeaya BiosciencesNASDAQ: IDYAKura OncologyNASDAQ: KURAKymera TherapeuticsNASDAQ: KYMRORIC PharmaceuticalsNASDAQ: ORICParabilis MedicinesNASDAQ: PBLSRelayNASDAQ: RLAYSilence TherapeuticsNASDAQ: SLNTYRA BiosciencesNASDAQ: TYRAZymeworksNASDAQ: ZYMEVividion Therapeuticsacq. by BayerPeloton Therapeuticsacq. by MerckSilverback Therapeuticsacq. by ARS PharmaceuticalsTubulis GmbHacq. by Gilead Sciences
Portfolio news
latest coverage across their companies
Silence Therapeutics · biospace.com · Sep 2, 2026
Black Diamond Therapeutics, Inc · finance.yahoo.com · Sep 2, 2026
Flare Therapeutics · globenewswire.com · Jun 30, 2026
Arrakis Therapeutics · biospace.com · Jun 25, 2026
Blueprint Medicines · trysignalbase.com · Mar 25, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Ideaya Biosciences | 4.6% | $10.00 | May 2019 | $9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Nextech Invest made?
- Nextech Invest has 77 tracked investments, 28 of which have exited, including 8 dated in the last 24 months.
- What stage does Nextech Invest invest at?
- Nextech Invest invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Nextech Invest's typical check size?
- Nextech Invest typically writes checks of $648K – $3.2M.
- What sectors does Nextech Invest focus on?
- Nextech Invest focuses on Biotech, Healthtech, Medical Devices.
- Where is Nextech Invest located?
- Nextech Invest is headquartered in Zurich, CH.
- Does Nextech Invest lead rounds?
- Nextech Invest has led 6 of the 15 rounds where its role is on record.
- Who does Nextech Invest co-invest with?
- Nextech Invest most often shares deals with Foresite Capital, RA Capital, Wellington Management, among 129 tracked co-investors.
Co-investors · 26
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
The Column Group (TCG) is a venture capital ecosystem focused on the life sciences, funding scientific innovation and building biotech companies from formation through exit.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
▶14 more co-investors
OUP (Osage University Partners)venBio PartnersVersant VenturesGeneral CatalystF-Prime Capital5AM VenturesFrazier Healthcare PartnersLux CapitalUS Venture PartnersForbionSignalFire8VCTwo Sigma VenturesNew Leaf Venture Partners
Firms observed investing alongside Nextech Invest, from public investor directories. Shared companies are the overlap with Nextech Invest's recorded portfolio.
Similar investors
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.